11 articles with NLS Pharma
NLS Pharmaceutics Announces Issuance of Canadian Patent Covering its Novel Formulation of Controlled-Release Mazindol (Mazindol CR)
NLS Pharmaceutics Ltd.announces that it has been awarded Canadian Patent No. 3016852, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD).
NLS Pharmaceutics Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex® (Mazindol)
Agreement provides exclusive rights to all available data included in the original new drug application for mazindol in the U.S.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces the closing of its initial public offering of 4,819,277 units
NLS Pharmaceutics Ltd. Announces Notice of Allowance of a New Technology Patent Covering Attention Deficit Hyperactivity Disorder & Narcolepsy
NLS Pharmaceutics Ltd., a Swiss biotech firm focusing on the development of novel treatments of rare neurological diseases including narcolepsy, idiopathic hypersomnia and Kleine-Levin Syndrome and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder, announced that the European Patent Office issued a Notice of Intention to Grant NLS's patent application covering a novel formulation of mazindol for treatment of ADHD and sleep related disorders.
NLS Pharma Announces New Information In Support Of The Mechanism Of Action Of Its Lead Compound NLS-1 Mazindol CR
NLS Pharma Announces Phase ll Study Of NLS-1 (Mazindol) In Adult ADHD Patients Has Met All Primary And Secondary Endpoints
NLS Pharma Announces Completion Of Phase II Study For NLS-1, Its Lead ADHD Compound; New Investors, New Patents
NLS Pharma Announces Submission Of Investigational New Drug (IND) Application To FDA For Its Controlled-Release Mazindol For The Treatment Of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)